On April 13, 2021, Dr. Joanne Donovan notified Catabasis Pharmaceuticals, Inc. (the “Company”) that she would resign from her position as Chief Medical Officer of the Company, effective as of April 23, 2021, and that she would be joining a company that is working towards developing treatments for Duchenne Muscular Dystrophy.